Business
Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million
Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million
About this update from Dicot Pharma Ab
Uppsala, Sweden, May 8, 2026. The Board of Directors of Dicot Pharma AB (”Dicot Pharma” or the "Company") announced on April 28, 2026 its intention to resolve on a rights issue with preferential rights for the Company's existing shareholders (the "Issue"), consisting of shares and warrants (”Units”), of approximately SEK 210 million. Pursuant to the authorization granted by the Annual General Meeting on May 6, 2026, the Board of Directors has today resolved to carry out the Issue. The subscription price has been set at SEK 1.36 per Unit, corresponding to SEK 0.17 per share (the warrants are issued free of charge). The subscription price per share corresponds to a discount of approximately 35.9 percent in relation to the closing price on May 7, 2026, which corresponds to a TERP discount (the theoretical price after separation of subscription rights) of approximately 25.7 percent. The Company has received subscription undertakings from larger existing shareholders, members of the Board of Directors and members of management totaling approximately SEK 17.7 million, corresponding to approximately 8.4 percent of the Issue. Guarantee commitments have been received from Schonfeld Global Master Fund LP, Anavio Capital Partners LLP and Vator Securities, amounting to approximately SEK 150.5 million, corresponding to approximately 71.6 percent. The guarantees have been provided on customary terms. Accordingly, subscription undertakings and guarantee commitments amount to approximately SEK 168 million, corresponding to approximately 80 percent of the Issue, providing Dicot Pharma with sufficient funds to finance the planned phase 2b study.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.SummaryThe purpose of the Issue is primarily to finance the planned clinical phase 2b study with the drug candidate LIB-01, which is intended to commence during the second half of 2026. In the evaluation of various financing alternatives for the planned clinical phase 2b study, the Board of Directors has concluded that a rights issue prioritizing existing s...